Clinical Efficacy of Pancreatin Minimicrospheres Supplementation in Patients with Exocrine Pancreatic Insufficiency (EPI) : Real-world Evidence

Background : Exocrine pancreatic insufficiency (EPI), characterized by reduced secretion or activity of pancreatic enzymes, causes improper absorption of food, excessive fat excretion in the stool, and malnourishment. Methods : In this observational, real-world evidence study, patients with one or more of the following condition were enrolled: abdominal pain, acidity, diarrhea, nausea, or dyspepsia (as per ROME III criteria). Patients had either been diagnosed with gallstones, hypertriglyceridemia, alcohol consumption or undergone abdominal surgery. Patients were prescribed capsule EnzigestTM10000 (pancreatin minimicrospheres) for one month.The severity and frequency of various gastric symptoms was measured at day 0 and day 30. Results : 540 patients were enrolled with a mean age of 51.6 years. Enzigest significantly reduced the severity of functional dyspepsia by 88.67% (p<0.001) as per Rome III Criteria. There is significant improvement in frequency of symptoms (83.80%), abdominal pain severit(81.58%), epigastric pain (83.09%), nausea (84.35%) and vomiting by 89.62% (all P<0.001). The overall improvement in symptoms was significant (p<0.001). Enzigest was well tolerated.Conclusion : Enzigest improved abdominal pain, dyspepsia, and acidity in patients with exocrine pancreatic insufficiency due to alcohol consumption, gallstones, hypertriglyceridemia, diuretic (Furosemide or Thiazide) or abdominal surgery. Enzigest containing pancreatin minimicrospheres can be an easy therapeutic option to counteract EPI.

Research advances in abnormal activation and secretion of pancreatic enzymes in acute pancreatitis / 临床肝胆病杂志

Abnormal activation and secretion of pancreatic enzymes in pancreatic acinar cells is one of the important pathogeneses of acute pancreatitis (AP) and can directly damage the pancreatic tissue to accelerate disease progression and induce severe AP. At present, the drugs inhibiting the abnormal activation and secretion of pancreatic enzymes tend to have an unsatisfactory effect in clinical practice, and therefore, it is of great importance to search for new therapeutic targets. This article summarizes the pathological events of abnormal activation and secretion of pancreatic enzymes (cytoplasmic calcium overload, colocalization of lysosomes and zymogen granules, organelle injury, obstructed apical secretion of trypsin, and increased basal secretion of trypsin), collects the molecular mechanisms of related events, and discusses the role of abnormal activation and secretion of pancreatic enzymes in the early stage of AP, so as to provide ideas for the development of targeted drugs in the future.

Treatment of postprandial discomfort syndrome in the elderly: a multi-centered prospective randomized controlled clinical study / 中华内科杂志

Objective@#To evaluate the efficacy and safety of Oryz-Aspergillus enzyme and pancreatin tablets (Combizym®) in the treatment of postprandial distress syndrome (PDS) in the elderly, compared with gastrointestinal motility drugs.@*Methods@#A prospective randomized controlled trial was designed and registered in the China Clinical Trials Registry (ChiCTR-IPR-16008185). The elderly patients with PDS were randomly divided into three groups, including Mosapride group with Mosapride citrate tablets 5 mg 3 times per day for 2 weeks; Combizym® group with Combizym tablets 244 mg 3 times per day for 2 weeks; combined treatment group with both drugs and same doses for 2 weeks. The modified Nepean dyspepsia index (NDSI) score, discomfort intensity score and PDS score were calculated on patients before treatment, at the end of first and second week of treatment, as well as 4 weeks after treatment finished, respectively. Adverse effects were evaluated.@*Results@#A total of 323 patients from 16 tertiary hospitals in China were enrolled in this study. Among them, 105 patients were in Mosapride group, 109 in Combizym® group and 109 in combined treatment group. There were 148 males (45.8%) and 175 females (54.2%) with median age 71.4±9.0 years (60-100 years). Baseline characteristics of three groups were comparable. After treatment, the NDSI scores in three groups all decreased significantly (P<0.001), while they were similar between groups (P>0.05). The discomfort intensity score and PDS score in three groups showed a significant reduction after treatment (P<0.001), especially in the combined treatment group. Compared with Mosapride group, the scores in Combizym® group decreased significantly after one or two weeks [discomfort intensity score: after one week, 4.0(2.5, 8.0) vs. 6.0(3.0, 10.0); after two weeks, 3.0(0.0, 5.0) vs. 4.0(2.0, 6.0); all P<0.05. PDS score: after one week, 6.0(3.0, 9.0) vs. 7.0(3.5, 10.5); after two weeks, 3.0(0.0, 5.0) vs. 4.0(2.0, 7.0); all P<0.05]. The efficacy rate in all patients after first week of treatment was over 15.0%. The efficacy rates after two weeks were 55.2%, 68.8% and 73.4% in Mosapride group, Combizym® group and combined treatment group, respectively. After two week treatment, the efficacy rates in Combizym® group (P=0.041) and combined group (P=0.006) were higher than that of Mosapride group. The recurrence rate of Mosapride group was 9.5%, which was significantly higher than that of Combizym® group (1.8%, P<0.05) and combined treatment group (1.8%, P<0.05). There were no serious adverse effects in the three groups.@*Conclusions@#The efficacy of Oryz-Aspergillus enzyme and pancreatin tablets is comparable with that of Mosapride in elderly PDS patients, with fewer adverse effects and low recurrence rate. Combination regimen indicates better efficacy than that of Oryz-Aspergillus enzyme and pancreatin tablets or Mosapride alone.

¿Es una alternativa terapéutica la pancrelipasa (Zenpep®) para pacientes con fibrosis quística?: síntesis rápida de evidencia / Is pancrelipase (Zenpep®) a therapeutic alternative for patients with cystic fibrosis?: rapid evidence synthesis

ANTECEDENTES Y OBJETIVO La fibrosis quística es una enfermedad multisistémica asociada a un componente genético, que se caracteriza por la presencia constante de secreciones en múltiples órganos, siendo las exacerbaciones pulmonares las que conllevan la mayor morbilidad y mortalidad. El Ministerio de Salud, a través del plan de Garantías Explícitas en Salud (GES), comprende dentro de su cobertura para esta condición de salud, las terapias de reemplazo enzimático para insuficiencia pancreática. Sin embargo, existe un único laboratorio que cuenta con registro sanitario en Chile (pancreatina). De esta forma, se le ha solicitado al Ministerio la inclusión de otras alternativas terapéuticas disponibles y, en particular de pancrelipasa (Zenpep®). En este contexto la Secretaría Técnica GES solicita una síntesis de evidencia con el objetivo de informar la toma de decisiones respecto de si es posible contar con una alternativa terapéutica a la pancreatina (Creon®) para pacientes con fibrosis quística. METODOLOGÍA Se formula una estrategia de búsqueda para ser utilizada en las bases de datos Epistemonikos, la Biblioteca Cochrane, y PubMed con el objetivo de identificar revisiones sistemáticas que abordaran la pregunta formulada. Al no encontrarse revisiones que abordaran las comparaciones deseadas, se realizó una búsqueda de estudios primarios en PubMed. Los resultados de la búsqueda se presentan en los hallazgos del presente documento. Se utiliza la metodología de certeza de la evidencia GRADE. Se incluyeron todas las preparaciones de pancrelipasa con cualquier nombre comercial. Se utilizó como comparador único placebo, priorizando éste por sobre la pancreatina. RESULTADOS Se utilizan 8 estudios primarios, de los cuales se obtienen los siguientes resultados: -En comparación a placebo, el uso de pancrelipasa en niños con fibrosis quística, podría au mentar la absorción de grasa y nitrógeno en un 34,5% y 34.6%, respectivamente. -La utilización de pancrelipasa en población adulta con fibrosis quística, podría aumentar la absorción de grasa y nitrógeno en un 38.5% y 34.5%, respectivamente. -La pancrelipasa no cuenta con registro sanitario vigente en Chile por lo que, de momento, habría que esperar la solicitud de registro, para incorporarla como alternativa terapéutica en pa cientes tratados en nuestro país.

Investigation on enzymatic degradation stability of peptide drugs LXT101 and its structural modified analogs in pancreatin system / 国际药学研究杂志

Objective To find the efficient modification groups of anti-proteinase hydrolyzation in polypeptide by investigat-ing and comparing the relation between the functional groups and their ability to inhibit proteinase hydrolyzation. Methods Reverse phase-high performance liquid chromatography(RP-HPLC)method was developed to investigate in vitro metabolisms of new drug LXT101 and its structural modified analogs LZN series and LMP series in pancreatin system. All the separations of peptide drugs and their digested fragments were monitored at 225 nm. Results The good linear range was 4.0-400 μg/ml(r>0.9990)for new drug LXT101 and its structural modified analogs,i.e.,LZN series and LMP series. The recoveries of all peptide drugs ranged from 95.0%to 98.7%in pancreatin systems. The relative standard derivations(RSD)of intra-day and inter-day were less than 1.5%and 2.5%,re-spectively. The revealed order of digested half-life of the peptide drugs was LZN series>LMP series>LXT101. Conclusion The study of different sites and different functional groups on the lifetime indicates that the half-lives of peptides are prolonged by introducing the functional groups in the suitable sites of peptide,which feature as proteinase inhibitors,such as carbamoyl(Cbm),acetyl(Ac),para-amino-phenylalanine(Aph)or para-uramido-phenylalanine(Uph),which work as either proton donor or acceptor. Our results can pro-vide some useful and valuable information on structural design of peptide drug with long lifetime and high activity.

Efficacy of Drugs with Different Mechanisms of Action on Functional Dyspepsia:A Comparative Study / 胃肠病学

Background:Oryz-Aspergillus Enzyme and Pancreatin Tablet is a double-deck digestive enzyme pellet containing Oryz-Aspergillus enzyme and pancreatin that has been widely used for treatment of functional dyspepsia (FD)in clinical practice. However,there is no randomized controlled trial focusing on the efficacy of this agent versus other drugs used for treatment of FD such as prokinetics and proton pump inhibitors (PPI). Aims:To compare the efficacy and safety among Oryz-Aspergillus Enzyme and Pancreatin Tablet,Domperidone Tablet and Esomeprazole Magnesium Enteric-coated Tablet, three drugs with different mechanisms of action on FD,in Chinese population. Methods:A total of 82 Helicobacter pylori-negative outpatients fulfilling the diagnostic criteria of FD in Rome Ⅲ were recruited from Nov. 2015 to Jun. 2016 at the First Affiliated Hospital of Zhejiang Chinese Medical University. These patients were randomly allocated into 3 groups,and received Oryz-Aspergillus Enzyme and Pancreatin Tablet (group A),Domperidone Tablet (group B)and Esomeprazole Magnesium Enteric-coated Tablet (group C)orally for 4 weeks,respectively. The improvement of dyspeptic symptoms and adverse events were observed and recorded. Results:After 4 weeks treatment,the overall efficacies for global symptoms in group A,group B and group C were 93. 1%,88. 9% and 69. 2%,respectively,statistically significant difference was existed among the three groups (P < 0. 05). Domperidone Tablet was effective for postprandial fullness and early satiety;Esomeprazole Magnesium Enteric-coated Tablet was sensitive for epigastric pain,epigastric burning,and belching and regurgitation;the efficacies of Oryz-Aspergillus Enzyme and Pancreatin Tablet for all five dyspeptic symptoms were in between. No adverse events were observed during treatment course. Conclusions:Digestive enzymes,prokinetics and PPI have different sensitive symptoms and optimal indications for treatment of FD. The overall efficacy of Oryz-Aspergillus Enzyme and Pancreatin Tablet is superior to that of prokinetics and PPI.

Significance of oral pancreatin enzyme capsules on life quality of patients with total gastrectomy / 中国生化药物杂志

Objective To explore the clinical significance of oral pancreatin capsules for patients after total gastrectomy.Methods Ninety cases of total gastrectomy patients in Nanyang City Center Hospital were selected and randomly divided into trypsin group and control group,with 45 patients in each group.The control group were treated by conventional therapy,and the patients of trypsin group were treated by pancreatin capsules on the basis of conventional therapy after 3 weeks postoperation.Scores of EORTC QLQ-C30,korenaga and fecal fat contents were compared between two groups six months postoperation.Results No statistically significant difference was found in the scoring system of EORTC QLQ-C30,korenaga and fecal fat contents in two groups before administered,The score of role function,emotional function and overall health status in the scoring system of EORTC QLQ-C30 of patients in trypsin group were higher than control group after 6 months administration.The differences were statistically significant (P7g in trypsin group was lower than control group at 24 h.The differences were statistically significant (P<0.05).Conclusion Oral pancreatin capsules could significantly improve the quality of life of patients after total gastrectomy, which is worthy of promoting.

Action of a pancreatin and an Aspergillus oryzae protease on whey proteins: correlation among the methods of analysis of the enzymatic hydrolysates

The objectives of this study were to hydrolyze whey proteins using a pancreatin and an Aspergillus oryzae protease; to evaluate the degree of hydrolysis (DH) and the peptide profile; and to establish the correlations among the analytical methods. Ten hydrolysates were prepared at different reaction times and the highest DH was obtained by the protein content method. Good correlations (r > 0.87) between the methods of formaldehyde and orthophthalaldehyde (OPA), formaldehyde and osmometry as well as osmometry and OPA were observed using pancreatin. Similar results were obtained between OPA and soluble protein content for the A. oryzae protease. The action of pancreatin produced the highest contents of di- and tripeptides (9.07, 7.12 and 6.46%) and the lowest of large peptides (42.43, 41.33 and 41.13%), after 3, 4 and 5 h of hydrolysis, respectively. Using pancreatin, the DH measured by formol titration and OPA was positively correlated with medium peptide content and negatively correlated with large peptide content. For the A. oryzae protease, a strong negative correlation was observed between the large peptide content and the DH measured by the OPA method.

The impact of exogenous trypsin supplement on the quality of life of patients after total gastrectomy / 中华普通外科杂志

Objective To improve the quality of life in gastric cancer patients after total gastrectomy by exogenous trypsin supplement.Method In this study 106 patients were divided into two groups,with 53 patients in each group,oral pancreatic enzyme capsule was given in comparison without in control group.Patients were asked to fill in EORTC QLQ-C30 questionnaire and Korenaga questionnaire at half a year postoperation,stool sample was collected at the same time for fecal fat assay.Results A total of 86 patients completed this test at postoperation half a year.With a comprehensive assessment of quality of life in patients by the scoring system of EORTC QLQ-C30 and Korenaga and the fecal fat contents measurement.Exogenous trypsin plays a positive role in preventing weight loss,improving emotional function,alleviating loss of appetite,insomnia,fatigue,postprandial fullness,nausea,vomiting and diarrhea,and improving intestinal tolerance to fat and the overall health status of patients.Conclusions Total gastrectomy causes exocrine pancreatic dysfunction,exogenous supplement of the enzyme improves postoperative quality of life in these patients.

Combination therapy of azintamide and domperidone in functional dyspepsia: a randomised, double-blind, placebo-controlled trial / 中华内科杂志

Objective To study the efficacy and safety of combined therapy of compound azintamide and domperidone in functional dyspepsia. Methods A randomised, double-blind, placebo-controlled trial.Two hundred and eight patients with functional dyspepsia were randomly grouped into group A (experimental group, 102 cases) and group B (control group, 106 cases). The patients in the group A were given 2 tablets of compound azintamide 3 times a day in addition to domperidone 10 mg 3 times per day for four weeks. The patients in the group B were only given domperidone 10 mg 3 times per day for 4 weeks. The therapeutic efficacy was evaluated by modified Severity of Dyspepsia Assessment (mSODA) and Global Patient Assessment (GPA). Results Subscore in mSODA:the change of bloating/pain intensity score in group A is -12.35±5.48 while group B is -10.52±4.65(P=0.009), the change of non-bloating/pain symptoms score in group A is -5.75±3.31 while group B is - 4. 86 ± 2.65 (P=0.033), and the change of satisfaction score in group A is 7. 09 ± 3. 78 while group B is 5.62 ± 3. 54 (P = 0. 004). The response rate in group A is 89. 2% which is significantly higher than 76.4% in group B (P=0. 015). Other symptoms for response assessment included loss of appetite, early satiety, fullness after meal, diarrhea. No severe side-effect was found in both groups. Conclusions Combined therapy of compound azintamide and domperidone may lead to bigger improvement in overall efficacy and health related quality of life in patients with functional dyspepsia than use of motility medicine alone. Potential mechanisms that may account for the efficacy of compound azintamide in functional dyspepsia include modulation of visceral sensitivity and/or gastrointestinal motility.

Novel agents for enzymatic and fungal hydrolysis of stevioside / Novos agentes para a hidrólise enzimática e fúngica do esteviosídeo

A comparative study on the potential of some biological agents to perform the hydrolysis of stevioside was carried out, aiming at establishing an alternative methodology to achieve the aglycon steviol or its rearranged derivative isosteviol, in high yields to be used in the preparation of novel bioactive compounds. Hydrolysis reactions were performed by using filamentous fungi (Aspergillus niger, Rhizopus stolonifer and Rhizopus arrhizus), a yeast (Saccharomyces cerevisiae) and enzymes (pancreatin and lipases PL250 and VFL 8000). Pancreatin showed the best hydrolytic activity, furnishing isosteviol at 93.9% of yield, at pH 4.0, using toluene as a co-solvent. Steviol was produced using both pancreatin at pH 7.0 (20.2% yield) and A. niger atpH 7 (20.8% yield).

Um estudo comparativo do potencial de alguns agentes biológicos capazes de hidrolisar o esteviosídeo foi realizado,objetivando-se estabelecer uma metodologia alternativa para a obtenção da aglicona esteviol ou seu produto de rearranjo, isoesteviol, em rendimentos elevados que permitam o uso destas agliconas para o preparo de novos compostos bioativos. As reações de hidrólise foram realizadas usando fungosfilamentosos (Aspergillus niger, Rhizopus stolonifer e Rhizopus arrhizus), uma levedura (Saccharomyces cerevisiae) e enzimas(pancreatina, lipase PL250 e lipase VFL 8000). A pancreatina mostrou a melhor atividade hidrolítica dentre os sistemastestados, fornecendo isoesteviol com rendimento de 93,9% em pH 4,0, usando tolueno como co-solvente. Esteviol foi produzido tanto usando pancreatina em pH 7,0 (20,2% derendimento) quanto usando A. niger em pH 7,0 (20,8% de rendimento).

Ação da pancreatina na obtenção de hidrolisados protéicos de soro de leite com elevado teor de oligopeptídeos / Action of pancreatin for obtaining whey protein hydrolysates with high oligopeptide contents

Vários hidrolisados enzimáticos de soro de leite foram preparados visando a elevação do teor de oligopeptídeos e a redução de custos para produção em larga escala. Para isso, empregou-se a pancreatina e alguns parâmetros hidrolíticos como o tempo de reação (5, 10 e 15h), a relação E:S (1:100, 2:100 e 4:100) e a concentração do substrato (10 e 15 por cento) foram testados. Os hidrolisados foram fracionados por cromatografia liquida de alta eficiência de exclusão molecular (SEHPLC) e, para a quantificação dos componentes das frações cromatográficas, empregou-se o método rápido da Área Corrigida da Fração. Para os parâmetros estudados, observou-se efeito benéfico sobre o perfil peptídico, sendo que o melhor resultado, associado, principalmente, ao maior teor de oligopeptídeos (49 por cento) e ao menor conteúdo de aminoácidos livres (22 por cento), foi obtido quando se empregou a concentração do substrato a 10 por cento, a relação E:S de 4:100 e o tempo de reação de 10h.

Several enzymatic hydrolysates of whey were prepared with the objective of increasing the oligopeptide content and reducing the cost of large scale production. Pancreatin was used and some hydrolytic parameters such as reaction time (5, 10 and 15h), enzyme:substrate ratio (E:S) (1:100, 2:100 and 4:100) and substrate concentration (10 and 15 percent) were tested. The hydrolysates were fractionated by size-exclusion-HPLC and the rapid corrected fraction area method was used for quantifying the chromatographic fractions. The beneficial effect on the peptide profile was observed in several cases, and it was mainly associated with higher oligopeptide (49 percent) and lower amino acid (22 percent) contents, which were obtained for a substrate concentration of 10 percent, E:S ratio of 4:100 and reaction time of 10h.

Imobilização da pancreatina em carvão ativado e em alumina para o preparo de hidrolisados de soro de leite / Immobilization of pancreatin in activated carbon and in alumina for preparing whey hydrolysates

Tendo como objetivo a redução de custos do processo de fabricação de hidrolisados protéicos, estudou-se neste trabalho a imobilização da pancreatina, por adsorção, em carvão ativado e em alumina. Para isso, foram testadas diferentes condições de imobilização (30, 60 e 90min a 25°C, e 12h a 5°C). Para verificar a taxa de imobilização, determinou-se indiretamente a enzima não adsorvida nos suportes. Ao se utilizar o carvão ativado, não foi observada diferença significativa entre as condições testadas, tendo-se obtido 100% de imobilização enzimática. Para a alumina, a melhor condição foi a de 90min, na qual se obteve 37% de imobilização. A medida do grau de exposição da fenilalanina, pela espectrofotometria derivada segunda, foi empregada para a determinação da estabilidade operacional da enzima, tendo sido mostrado que a imobilização em carvão ativado e em alumina permitiu a reutilização da pancreatina por até 5 vezes e 2 vezes, respectivamente.

Immobilization of pancreatin in activated carbon and in alumina was studied for producing protein hydrolysates, in order to reduce the process costs. Different immobilization conditions were tested (30, 60 and 90min at 25°C, and 12h at 5°C). For estimating the immobilization rate the amount of the non-adsorbed enzyme on the supports was indirectly determined. When activated carbon was used, no significant difference was observed among the tested conditions, obtaining 100% of enzymatic immobilization. In case of alumina, the best condition showed to be the 90min treatment which produced 37% of immobilization. The evaluation of the degree of exposition of phenylalanine, by second derivative spectrophotometry, was used for the determination of the enzyme operational stability, and showed that the immobilization in activated carbon and in alumina allowed the reusability of the pancreatin for 5 times and 2 times, respectively.

Development of human articular cartilage derived microcarrier / 中华骨科杂志

Objective To develop a method to prepare human articular cartilage derived microcarrier for both rapid propagating chondrocytes and being used as scaffold to support chondrogenesis. Methods Human articular cartilage was crushed into small pieces by muller after lyophilization, and sorted through two different meshes to collect only those specimens measuring 150-200 microns. Then, in turn, the specimens were subjected to 0.25% trypsin at 37 ℃ for 24 hours and 1% Triton X-100 for 72 hours, respectively. The specimens were observed by inverted phase contrast microscopy, and assessed by staining with haematoxylin-eosin, safranin-O (for GAG), as well as by the immunohistochemistry of aggrecan, collagen type Ⅱ. The microcarriers were seeded with human chondrocytes after being irradiated by 60Co. Results Using inverted phasecontrast microscope, the freezing-dry cartilage particles were observed as yellow, different shapes, and their surfaces were uneven, and with many pits. After treating with trypsin and Triton X-100, the microcarriers showed light yellow, without cartilage morphology. The microcarriers became flocculous or like a hairbrush, and the area of contacting surface significant increased. After culture with cartilage cell for 2 hours, lots of spherical chondrocytes adhered to the microcarriers. HE stain of section confirmed that the celluar constituents of the specimens were removed, the specimens stained weakly positive for GAG, negatively for aggrecan, and positively for collagen type Ⅱ, respectively. Conclusion The detergent and trypsin can remove the cellular constituents and knock out the aggrecan from human articular cartilage while maintaining collagen type Ⅱ and GAG, and made the cartilage pieces flocculous or hairbrush-like. The chondrocytes can be well maintained in human articular cartilage derived microcarriers. Human articular cartilage derived microcarriers were prepared successfullly.

Cpn60 deficiency may play a role in the intrapancreatic enzyme activation in acute pancreatitis / 中国病理生理杂志

AIM: To investigate the change of Cpn60 content,the alterations of pancreatic enzymes and lysosome,in order to better understand the mechanism of intrapancreatic enzyme activation in acute pancreatitis(AP). METHODS: The AP model was replicated by retrograde infusion of 4% sodium-deoxycholate in the choledocus of SD rats. The levels of amylase in plasma and TNF-? in pancreatic tissue were measured by biochemical technique at 5 h and 10 h after AP induction. The content of Cpn60 and pancreatic enzymes in different compartments of the acinar cells were tested by quantitative protein A-gold immunocytochemistry technique. The change of lysosome in the acinar cells was observed under the electronic microscope. RESULTS: After AP was induced,the levels of amylase in the plasma and TNF-? in the pancreatic tissue increased significantly. Lysosomes with different forms were found inside the acinar cells,and some of them located in the Golgi apparatus. Cpn60 content decreased,which was accompanied by an increase of lipase or chymotrypsinogen content in the pancreatic secretory pathway. CONCLUSION: In the pancreatic acinar cells of AP rats,Cpn60 content decreased,suggesting an insufficient chaperone capacity,and combining with the change of lysosome both in its amount and location,which may take part in the intrapancreatic enzyme activation and the development of AP.

STUDY ON ANGIOTENSIN CONVERTING ENZYME INHIBITORY PEPTIDES FROM DIGESTION OF SOY PROTEIN IN VITRO / 营养学报

Objective: To investigate if angiotensin converting enzyme inhilitory(ACEI) peptides would be produced from SPI digested by a batch digestion system using enzymes similar to digestive enzymes in humans.Method: Simulate the conditions of human gastrointestinal digestion in a model digestion system in vitro and produce soy peptides from SPI digested using pepsin and pancreatin.In addition to monitoring ACEI activity in the total soy protein digest,the possibility of generating soy peptide fractions with more potent activity than the unfractionated digest was investigated by measuring activity of fractions obtained after ultrafitration,anion exchange,and RP-HPLC.Results: The generation of ACEI activity in SPI was determined after sequential digestion with pepsin and pancreatin.The inhibitory activity was highest within the first 20 min at pepsin digestion and decreased upon subsequent digestion with pancreatin.An IC50 value of 0.28?0.06 mg/ml was determined after 180 min of digestion,while no ACEI activity was measured for the undigested SPI at 0.73 mg/ml.Chromatographic fractionation of the SPI digest resulted in IC50 values of active fractions ranging from 0.13?0.03 to 0.93?0.08 mg/ml.Conclusion: Many different peptides with ACEI activities were produced after pepsin-pancreatin digestion of SPI in vitro and lead to the speculation that physiological gastrointestinal digestion could also yield ACE inhibitory peptides from SPI.